|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C16orf58 |
Gene summary for C16ORF58 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C16orf58 | Gene ID | 64755 |
| Gene name | RUS family member 1 | |
| Gene Alias | C16orf58 | |
| Cytomap | 16p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024QZE6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64755 | C16orf58 | C51 | Human | Oral cavity | OSCC | 1.29e-09 | 4.31e-01 | 0.2674 |
| 64755 | C16orf58 | C57 | Human | Oral cavity | OSCC | 3.84e-07 | 2.33e-01 | 0.1679 |
| 64755 | C16orf58 | C06 | Human | Oral cavity | OSCC | 6.53e-04 | 6.27e-01 | 0.2699 |
| 64755 | C16orf58 | C08 | Human | Oral cavity | OSCC | 2.17e-15 | 3.51e-01 | 0.1919 |
| 64755 | C16orf58 | LN46 | Human | Oral cavity | OSCC | 1.63e-06 | 2.00e-01 | 0.1666 |
| 64755 | C16orf58 | LP15 | Human | Oral cavity | LP | 9.78e-07 | 7.74e-01 | 0.2174 |
| 64755 | C16orf58 | SYSMH1 | Human | Oral cavity | OSCC | 7.17e-03 | 1.33e-01 | 0.1127 |
| 64755 | C16orf58 | SYSMH2 | Human | Oral cavity | OSCC | 7.01e-07 | 2.15e-01 | 0.2326 |
| 64755 | C16orf58 | SYSMH3 | Human | Oral cavity | OSCC | 2.65e-07 | 1.94e-01 | 0.2442 |
| 64755 | C16orf58 | SYSMH5 | Human | Oral cavity | OSCC | 5.41e-06 | 1.28e-01 | 0.0647 |
| 64755 | C16orf58 | SYSMH6 | Human | Oral cavity | OSCC | 6.75e-05 | 1.72e-01 | 0.1275 |
| 64755 | C16orf58 | male-WTA | Human | Thyroid | PTC | 7.53e-40 | 3.29e-01 | 0.1037 |
| 64755 | C16orf58 | PTC01 | Human | Thyroid | PTC | 3.24e-14 | 9.97e-02 | 0.1899 |
| 64755 | C16orf58 | PTC04 | Human | Thyroid | PTC | 4.52e-20 | 1.76e-01 | 0.1927 |
| 64755 | C16orf58 | PTC05 | Human | Thyroid | PTC | 1.39e-08 | 2.71e-01 | 0.2065 |
| 64755 | C16orf58 | PTC06 | Human | Thyroid | PTC | 1.69e-21 | 4.28e-01 | 0.2057 |
| 64755 | C16orf58 | PTC07 | Human | Thyroid | PTC | 2.50e-32 | 3.39e-01 | 0.2044 |
| 64755 | C16orf58 | ATC12 | Human | Thyroid | ATC | 5.14e-14 | 2.03e-01 | 0.34 |
| 64755 | C16orf58 | ATC13 | Human | Thyroid | ATC | 3.77e-28 | 3.34e-01 | 0.34 |
| 64755 | C16orf58 | ATC2 | Human | Thyroid | ATC | 1.28e-03 | 6.63e-01 | 0.34 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C16orf58 | insertion | Nonsense_Mutation | novel | c.318_319insATACCTTAAAGGCAGTTTTATACAGTATTT | p.Leu106_Ser107insIleProTerArgGlnPheTyrThrValPhe | p.L106_S107insIP*RQFYTVF | Q96GQ5 | protein_coding | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| C16orf58 | insertion | Frame_Shift_Ins | novel | c.1117_1118insTTCTTGGGCCTGGTGCAGAGGCTCACACCTAT | p.Ala373ValfsTer18 | p.A373Vfs*18 | Q96GQ5 | protein_coding | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| C16orf58 | SNV | Missense_Mutation | c.574N>T | p.Thr192Ser | p.T192S | Q96GQ5 | protein_coding | deleterious(0) | benign(0.334) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| C16orf58 | SNV | Missense_Mutation | novel | c.799N>A | p.Leu267Ile | p.L267I | Q96GQ5 | protein_coding | deleterious(0.03) | possibly_damaging(0.491) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| C16orf58 | SNV | Missense_Mutation | novel | c.144N>A | p.Phe48Leu | p.F48L | Q96GQ5 | protein_coding | tolerated(0.13) | benign(0) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| C16orf58 | SNV | Missense_Mutation | c.1287N>T | p.Met429Ile | p.M429I | Q96GQ5 | protein_coding | deleterious(0.04) | benign(0) | TCGA-AY-4071-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C16orf58 | SNV | Missense_Mutation | c.548C>A | p.Pro183His | p.P183H | Q96GQ5 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| C16orf58 | SNV | Missense_Mutation | novel | c.992N>C | p.Val331Ala | p.V331A | Q96GQ5 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
| C16orf58 | SNV | Missense_Mutation | novel | c.436N>T | p.Arg146Cys | p.R146C | Q96GQ5 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C16orf58 | SNV | Missense_Mutation | rs150175927 | c.1220N>A | p.Arg407Gln | p.R407Q | Q96GQ5 | protein_coding | tolerated(0.62) | benign(0) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |